Show simple item record

dc.contributor.authorBennett, John M
dc.contributor.authorKaminski, Mark S
dc.contributor.authorLeonard, John P
dc.contributor.authorVose, Julie M
dc.contributor.authorZelenetz, Andrew D
dc.contributor.authorKnox, Susan J
dc.contributor.authorHorning, Sandra
dc.contributor.authorPress, Oliver W
dc.contributor.authorRadford, John A
dc.contributor.authorKroll, Stewart M
dc.contributor.authorCapizzi, Robert L
dc.date.accessioned2009-07-29T11:43:34Z
dc.date.available2009-07-29T11:43:34Z
dc.date.issued2005-06-15
dc.identifier.citationAssessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. 2005, 105 (12):4576-82 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid15731177
dc.identifier.doi10.1182/blood-2004-12-4690
dc.identifier.urihttp://hdl.handle.net/10541/75822
dc.description.abstractThe incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evaluated. A total of 1071 patients were enrolled in 7 studies: 995 with relapsed/refractory low-grade NHL, +/- transformation (median, 3 prior regimens [range, 1-13 regimens]) and 76 patients with previously untreated low-grade follicular NHL. A single dose of iodine tositumomab and I(131) tositumomab was administered. For tMDS/tAML patients, baseline and posttherapy peripheral blood and marrow specimens were reviewed in a blinded fashion. Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients. tMDS/tAML was reported in 35 (3.5%) of 995 patients (annualized incidence, 1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded review (annualized incidence of 1.1%/y [95% confidence interval, 0.7%-1.6%/y]). Of the 25 cases, 10 patients (40%) were diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical evidence to support such a diagnosis; and 13 (52%) were confirmed to have developed tMDS/tAML following RIT. This incidence is consistent with that expected on the basis of patients' prior chemotherapy for NHL. With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients).
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshClinical Trials as Topic
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshIodine Radioisotopes
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshLymphoma, Non-Hodgkin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshModels, Statistical
dc.subject.meshMyelodysplastic Syndromes
dc.subject.meshRadioimmunotherapy
dc.subject.meshRadiometry
dc.subject.meshRemission Induction
dc.subject.meshTime Factors
dc.subject.meshWhole-Body Irradiation
dc.titleAssessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.en
dc.typeArticleen
dc.contributor.departmentJames P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA. john_bennett@urmc.rochester.edu <john_bennett@urmc.rochester.edu>en
dc.identifier.journalBlooden
html.description.abstractThe incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evaluated. A total of 1071 patients were enrolled in 7 studies: 995 with relapsed/refractory low-grade NHL, +/- transformation (median, 3 prior regimens [range, 1-13 regimens]) and 76 patients with previously untreated low-grade follicular NHL. A single dose of iodine tositumomab and I(131) tositumomab was administered. For tMDS/tAML patients, baseline and posttherapy peripheral blood and marrow specimens were reviewed in a blinded fashion. Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients. tMDS/tAML was reported in 35 (3.5%) of 995 patients (annualized incidence, 1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded review (annualized incidence of 1.1%/y [95% confidence interval, 0.7%-1.6%/y]). Of the 25 cases, 10 patients (40%) were diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical evidence to support such a diagnosis; and 13 (52%) were confirmed to have developed tMDS/tAML following RIT. This incidence is consistent with that expected on the basis of patients' prior chemotherapy for NHL. With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients).


This item appears in the following Collection(s)

Show simple item record